Quarterly ResultAug 6, 2026, 07:31 AM
Tarsus Q2 Revenue $173.9M, Net Loss Narrows to $18.6M
AI Summary
Tarsus Pharmaceuticals reported a significant increase in Q2 2026 net product sales to $173.9 million, up from $102.7 million in Q2 2025, with net loss narrowing to $18.6 million from $20.3 million. The company also achieved positive cash flow from operations for the six months ended June 30, 2026, totaling $36.6 million. Despite these improvements, Tarsus continues to incur losses and faces risks related to its dependence on XDEMVY, market acceptance, and the need for potential future funding.
Key Highlights
- Q2 2026 net product sales increased to $173.9 million from $102.7 million YoY.
- Q2 2026 net loss narrowed to $18.6 million from $20.3 million YoY.
- Q2 2026 net loss per share was $(0.43), improved from $(0.48) YoY.
- Net cash provided by operations for H1 2026 was $36.6 million.
- Cash and cash equivalents stood at $204.6 million as of June 30, 2026.
- Recognized a $2.8 million gain on exchange of long-term investments in Q2 2026.
- Company relies heavily on XDEMVY commercialization and pipeline development.
- Identified risks include market acceptance, pricing, and supply chain dependence.
Price Impact
More from TARS